Characterizing Candida glabrata Pdr1, a Hyperactive Transcription Factor Involved in Azole Resistance.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2023
Historique:
medline: 10 4 2023
entrez: 6 4 2023
pubmed: 7 4 2023
Statut: ppublish

Résumé

This chapter illustrates how to prepare isogenic strains carrying gain-of-function forms of transcription factor Pdr1 in the human pathogen Candida glabrata. Simple steps are described that lead from a characterized plasmid-borne PDR1-GOF allele to its integration into the yeast genome in a markerless manner. Pdr1-GOF strains constructed by this approach are suitable for virulence studies in an animal host.

Identifiants

pubmed: 37024701
doi: 10.1007/978-1-0716-3155-3_11
doi:

Substances chimiques

Transcription Factors 0
Azoles 0
DNA-Binding Proteins 0
Fungal Proteins 0
Antifungal Agents 0
Fluconazole 8VZV102JFY

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-179

Informations de copyright

© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Tsai HF, Krol AA, Sarti KE, Bennett JE (2006) Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother 50(4):1384–1392. https://doi.org/10.1128/AAC.50.4.1384-1392.2006
doi: 10.1128/AAC.50.4.1384-1392.2006 pubmed: 16569856 pmcid: 1426987
Vermitsky JP, Edlind TD (2004) Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother 48(10):3773–3781. https://doi.org/10.1128/AAC.48.10.3773-3781.2004
doi: 10.1128/AAC.48.10.3773-3781.2004 pubmed: 15388433 pmcid: 521908
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD (2016) Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol 7:2173. https://doi.org/10.3389/fmicb.2016.02173
doi: 10.3389/fmicb.2016.02173 pubmed: 28127295
Bennett JE, Izumikawa K, Marr KA (2004) Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 48(5):1773–1777. https://doi.org/10.1128/aac.48.5.1773-1777.2004
doi: 10.1128/aac.48.5.1773-1777.2004 pubmed: 15105134 pmcid: 400565
Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, Rohde B, Bauser C, Bader O, Sanglard D (2009) Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog 5(1):e1000268. https://doi.org/10.1371/journal.ppat.1000268
doi: 10.1371/journal.ppat.1000268 pubmed: 19148266 pmcid: 2607542
Tsai HF, Sammons LR, Zhang X, Suffis SD, Su Q, Myers TG, Marr KA, Bennett JE (2010) Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother 54(8):3308–3317. https://doi.org/10.1128/AAC.00535-10
doi: 10.1128/AAC.00535-10 pubmed: 20547810 pmcid: 2916311
Zordan RE, Ren Y, Pan SJ, Rotondo G, De Las PA, Iluore J, Cormack BP (2013) Expression plasmids for use in Candida glabrata. G3 (Bethesda) 3(10):1675–1686. https://doi.org/10.1534/g3.113.006908
doi: 10.1534/g3.113.006908 pubmed: 23934995
Zheng L, Baumann U, Reymond JL (2004) An efficient one-step site-directed and site-saturation mutagenesis protocol. Nucleic Acids Res 32(14):e115. https://doi.org/10.1093/nar/gnh110
doi: 10.1093/nar/gnh110 pubmed: 15304544 pmcid: 514394
Khakhina S, Simonicova L, Moye-Rowley WS (2018) Positive autoregulation and repression of transactivation are key regulatory features of the Candida glabrata Pdr1 transcription factor. Mol Microbiol 107(6):747–764. https://doi.org/10.1111/mmi.13913
doi: 10.1111/mmi.13913 pubmed: 29363861 pmcid: 5842128
Simonicova L, Moye-Rowley WS (2020) Functional information from clinically-derived drug resistant forms of the Candida glabrata Pdr1 transcription factor. PLoS Genet 16(8):e1009005. https://doi.org/10.1371/journal.pgen.1009005
doi: 10.1371/journal.pgen.1009005 pubmed: 32841236 pmcid: 7473514
Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D (2011) Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One 6(3):e17589. https://doi.org/10.1371/journal.pone.0017589
doi: 10.1371/journal.pone.0017589 pubmed: 21408004 pmcid: 3052359
Vu BG, Moye-Rowley WS (2018) Construction and use of a recyclable marker to examine the role of major facilitator superfamily protein members in candida glabrata drug resistance phenotypes. mSphere 3(2):e00099. https://doi.org/10.1128/mSphere.00099-18
doi: 10.1128/mSphere.00099-18 pubmed: 29600281 pmcid: 5874441
Gietz RD, Schiestl RH (2007) High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc 2(1):31–34. https://doi.org/10.1038/nprot.2007.13
doi: 10.1038/nprot.2007.13 pubmed: 17401334
Paul S, Bair TB, Moye-Rowley WS (2014) Identification of genomic binding sites for Candida glabrata Pdr1 transcription factor in wild-type and rho0 cells. Antimicrob Agents Chemother 58(11):6904–6912. https://doi.org/10.1128/AAC.03921-14
doi: 10.1128/AAC.03921-14 pubmed: 25199772 pmcid: 4249425
Vu BG, Thomas GH, Moye-Rowley WS (2019) Evidence that Ergosterol biosynthesis modulates activity of the Pdr1 transcription factor in Candida glabrata. mBio 10:3. https://doi.org/10.1128/mBio.00934-19
doi: 10.1128/mBio.00934-19

Auteurs

Lucia Simonicova (L)

Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

W Scott Moye-Rowley (WS)

Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA. scott-moye-rowley@uiowa.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH